<?xml version="1.0" encoding="UTF-8"?>
<rss version="2.0" xmlns:atom="http://www.w3.org/2005/Atom">
<channel>
<title>Tempramed Technologies Ltd. — News on 6ix</title>
<link>https://6ix.com/company/tempramed-technologies-ltd</link>
<description>Latest news and press releases for Tempramed Technologies Ltd. on 6ix.</description>
<language>en-us</language>
<lastBuildDate>Wed, 29 Apr 2026 20:30:00 GMT</lastBuildDate>
<generator>6ix RSS</generator>
<atom:link href="https://6ix.com/rss/company/tempramed-technologies-ltd" rel="self" type="application/rss+xml" />
<image>
<url>https://6ix-events-pro.s3.amazonaws.com/6ixvideo/logos/org-logo69d6bc2fbeedb30cb6ffd29d.webp</url>
<title>Tempramed Technologies Ltd.</title>
<link>https://6ix.com/company/tempramed-technologies-ltd</link>
</image>
<item>
<title>TempraMed Announces Continuance into Ontario</title>
<link>https://6ix.com/company/tempramed-technologies-ltd/news/tempramed-announces-continuance-into-ontario</link>
<guid isPermaLink="true">https://6ix.com/company/tempramed-technologies-ltd/news/tempramed-announces-continuance-into-ontario</guid>
<pubDate>Wed, 29 Apr 2026 20:30:00 GMT</pubDate>
<description>Vancouver, British Columbia--(Newsfile Corp. - April 29, 2026) - TempraMed Technologies Ltd. (CSE: VIVI) (FSE: 9DY) ("TempraMed" or the "Company"), a medical-technology innovator transforming how temperature-sensitive medications are stored and managed, is pleased to announce that it has continued out of the provincial jurisdiction of British Columbia under the Business Corporations Act (British Columbia) into the provincial jurisdiction of Ontario under the Business Corporations Act (Ontario)..</description>
</item>
<item>
<title>TempraMed Announces Additional Granted Brazilian Patent for Newest VIVI Box Product</title>
<link>https://6ix.com/company/tempramed-technologies-ltd/news/tempramed-announces-additional-granted-brazilian-patent-for-newest-vivi-box-product</link>
<guid isPermaLink="true">https://6ix.com/company/tempramed-technologies-ltd/news/tempramed-announces-additional-granted-brazilian-patent-for-newest-vivi-box-product</guid>
<pubDate>Tue, 07 Apr 2026 11:00:00 GMT</pubDate>
<description>Grant in Brazil marks a major milestone in global IP strategy, advancing protection of its VIVI Box across key international marketsHighlightsBrazilian patent officially granted by the Brazilian Patent Office Covers core innovations underpinning TempraMed's VIVI Box™ multi-medication storage platform expected to market end of 2026Strengthens the Company's intellectual property position in one of the world's largest healthcare and consumer marketsSupports commercialization strategy and strategic.</description>
</item>
<item>
<title>TempraMed Signs LOI for Distribution Agreement in Panama, Expanding Central American Exposure</title>
<link>https://6ix.com/company/tempramed-technologies-ltd/news/tempramed-signs-loi-for-distribution-agreement-in-panama-expanding-central-american-exposure</link>
<guid isPermaLink="true">https://6ix.com/company/tempramed-technologies-ltd/news/tempramed-signs-loi-for-distribution-agreement-in-panama-expanding-central-american-exposure</guid>
<pubDate>Mon, 30 Mar 2026 11:00:00 GMT</pubDate>
<description>Vancouver, British Columbia--(Newsfile Corp. - March 30, 2026) - TempraMed Technologies Ltd. (CSE: VIVI) (FSE: 9DY) ("TempraMed" or the "Company"), a medical-technology innovator transforming how temperature-sensitive medications are stored and managed, is pleased to announce that it has signed a non-binding letter of intent ("LOI"), dated March 22, 2026, with TEM Consulting International S.A. ("TEM") a leading healthcare logistics and consultancy company based in the Panama, with respect to the</description>
</item>
<item>
<title>TempraMed Strengthens Global Intellectual Property Position with Granted Chinese Patent for Newest Product, VIVI Box</title>
<link>https://6ix.com/company/tempramed-technologies-ltd/news/tempramed-strengthens-global-intellectual-property-position-with-granted-chinese-patent-for-newest-product-vivi-box</link>
<guid isPermaLink="true">https://6ix.com/company/tempramed-technologies-ltd/news/tempramed-strengthens-global-intellectual-property-position-with-granted-chinese-patent-for-newest-product-vivi-box</guid>
<pubDate>Tue, 24 Mar 2026 11:00:00 GMT</pubDate>
<description>Grant in China marks a major milestone in global IP strategy, advancing protection of its VIVI Box platform across key international marketsHighlightsChinese patent officially granted by CNIPA on March 17, 2026Covers core innovations underpinning TempraMed's VIVI Box™ multi-medication storage platform expected to market end of 2026Strengthens the Company's intellectual property position in one of the world's largest healthcare and consumer marketsSupports commercialization strategy and strategic</description>
</item>
<item>
<title>TempraMed's Independently Validated Payer ROI Model for Reimbursement Further Reinforced by a Scientific Publication Highlighting Clinical and Economic Rationale for VIVI Cap</title>
<link>https://6ix.com/company/tempramed-technologies-ltd/news/temprameds-independently-validated-payer-roi-model-for-reimbursement-further-reinforced-by-a-scientific-publication-highlighting-clinical-and-economic-rationale-for-vivi-cap</link>
<guid isPermaLink="true">https://6ix.com/company/tempramed-technologies-ltd/news/temprameds-independently-validated-payer-roi-model-for-reimbursement-further-reinforced-by-a-scientific-publication-highlighting-clinical-and-economic-rationale-for-vivi-cap</guid>
<pubDate>Wed, 11 Mar 2026 11:00:00 GMT</pubDate>
<description>Peer-reviewed case report by Prof. Andreas Pfützner demonstrates real-world insulin protection during extreme heat exposure and aligns with previously validated savings modelVancouver, British Columbia--(Newsfile Corp. - March 11, 2026) - TempraMed Technologies Ltd. (CSE: VIVI) (FSE: 9DY) ("TempraMed" or the "Company"), a medical-technology innovator transforming how temperature-sensitive medications are stored and managed, today announced the publication of a clinical case report evaluating the</description>
</item>
<item>
<title>TempraMed Reports over 275 Clinicians Recommending VIVI Cap to Patients on Leading FrontrowMD Platform Across the United States</title>
<link>https://6ix.com/company/tempramed-technologies-ltd/news/tempramed-reports-over-275-clinicians-recommending-vivi-cap-to-patients-on-leading-frontrowmd-platform-across-the-united-states</link>
<guid isPermaLink="true">https://6ix.com/company/tempramed-technologies-ltd/news/tempramed-reports-over-275-clinicians-recommending-vivi-cap-to-patients-on-leading-frontrowmd-platform-across-the-united-states</guid>
<pubDate>Thu, 26 Feb 2026 12:00:00 GMT</pubDate>
<description>Partnership results in over 275 physicians recommending VIVI Cap to patients, strengthening clinical validation and driving scalable patient education and acquisitionVancouver, British Columbia--(Newsfile Corp. - February 26, 2026) - TempraMed Technologies Ltd. (CSE: VIVI) (FSE: 9DY) ("TempraMed" or the "Company"), a medical-technology innovator transforming how temperature-sensitive medications are stored and managed, is pleased to announce that more than 275 physicians across the United States</description>
</item>
<item>
<title>TempraMed Partners with Super-Pharm, Israel's Leading Pharmacy Chain to Commence a National Product Roll Out Strategy</title>
<link>https://6ix.com/company/tempramed-technologies-ltd/news/tempramed-partners-with-super-pharm-israels-leading-pharmacy-chain-to-commence-a-national-product-roll-out-strategy</link>
<guid isPermaLink="true">https://6ix.com/company/tempramed-technologies-ltd/news/tempramed-partners-with-super-pharm-israels-leading-pharmacy-chain-to-commence-a-national-product-roll-out-strategy</guid>
<pubDate>Tue, 10 Feb 2026 08:00:00 GMT</pubDate>
<description>Super-Pharm operates nationwide, serving millions of consumers annuallyVancouver, British Columbia--(Newsfile Corp. - February 10, 2026) - TempraMed Technologies Ltd. (CSE: VIVI) (FSE: 9DY) ("TempraMed" or the "Company"), a medical-technology innovator transforming how temperature-sensitive medications are stored and managed, is excited to announce the rollout of its products across Super-Pharm, Israel's largest and most prominent pharmacy and health-retail chain, operating nationwide and...</description>
</item>
<item>
<title>TempraMed Launches National Brick and Mortar Pharmacy Roll Out, Shipping Products to Maccabi Pharmacies Across Israel</title>
<link>https://6ix.com/company/tempramed-technologies-ltd/news/tempramed-launches-national-brick-and-mortar-pharmacy-roll-out-shipping-products-to-maccabi-pharmacies-across-israel</link>
<guid isPermaLink="true">https://6ix.com/company/tempramed-technologies-ltd/news/tempramed-launches-national-brick-and-mortar-pharmacy-roll-out-shipping-products-to-maccabi-pharmacies-across-israel</guid>
<pubDate>Fri, 06 Feb 2026 08:00:00 GMT</pubDate>
<description>Key Commercialization Milestone in Retail Pharmacy Network that Serves Over 2.8 Million Insured MembersVancouver, British Columbia--(Newsfile Corp. - February 6, 2026) - TempraMed Technologies Ltd. (CSE: VIVI) (FSE: 9DY) ("TempraMed" or the "Company"), a medical-technology innovator transforming how temperature-sensitive medications are stored and managed, is excited to announce that it has completed initial sales of VIVI Cap, VIVI Cap Smart, VIVI Epi, and VIVI Med to pharmacies operated by...</description>
</item>
<item>
<title>TempraMed Enters Strategic Media Partnership with Dr. Phil's Envoy Media, Validating Product Portfolio and Accelerating Market Adoption Across the United States</title>
<link>https://6ix.com/company/tempramed-technologies-ltd/news/tempramed-enters-strategic-media-partnership-with-dr-phils-envoy-media-validating-product-portfolio-and-accelerating-market-adoption-across-the-united-states</link>
<guid isPermaLink="true">https://6ix.com/company/tempramed-technologies-ltd/news/tempramed-enters-strategic-media-partnership-with-dr-phils-envoy-media-validating-product-portfolio-and-accelerating-market-adoption-across-the-united-states</guid>
<pubDate>Mon, 02 Feb 2026 08:00:00 GMT</pubDate>
<description>Access to an audience of over 19 million individuals monthly will expand national exposure, and supports scalable demand generation across B2C and B2B channels for TempraMed's full product portfolioVancouver, British Columbia--(Newsfile Corp. - February 2, 2026) - TempraMed Technologies Ltd. (CSE: VIVI) (FSE: 9DY) ("TempraMed" or the "Company"), a medical-technology innovator transforming how temperature-sensitive medications are stored and managed, is excited to announce that it has entered...</description>
</item>
<item>
<title>TempraMed Launches New Product "VIVI Med(TM)," Unlocking New Growth Opportunities in High-Value Biologics and Injectable Medications</title>
<link>https://6ix.com/company/tempramed-technologies-ltd/news/tempramed-launches-new-product-vivi-medtm-unlocking-new-growth-opportunities-in-high-value-biologics-and-injectable-medications</link>
<guid isPermaLink="true">https://6ix.com/company/tempramed-technologies-ltd/news/tempramed-launches-new-product-vivi-medtm-unlocking-new-growth-opportunities-in-high-value-biologics-and-injectable-medications</guid>
<pubDate>Fri, 23 Jan 2026 21:05:00 GMT</pubDate>
<description>Using same proprietary, patented technology, VIVI Med extends the product portfolio beyond injectable pens, opening access to broader patient populations, premium biologics, and institutional channelsHighlightsUses same fully patented, thermal-protection technology across product portfolio with four products in market that keep room temperature medications at optimal temperatureDesigned for medications beyond standard insulin pens, including vials, biologics, GLP-1 therapies, alternative...</description>
</item>
<item>
<title>TempraMed Receives Positive Response on Payor Reimbursement Model Driving Significant Return on Investment for Medical Payor Coverage</title>
<link>https://6ix.com/company/tempramed-technologies-ltd/news/tempramed-receives-positive-response-on-payor-reimbursement-model-driving-significant-return-on-investment-for-medical-payor-coverage</link>
<guid isPermaLink="true">https://6ix.com/company/tempramed-technologies-ltd/news/tempramed-receives-positive-response-on-payor-reimbursement-model-driving-significant-return-on-investment-for-medical-payor-coverage</guid>
<pubDate>Wed, 14 Jan 2026 07:00:00 GMT</pubDate>
<description>Validation is expected to accelerate TempraMed's path to payor reimbursement for product portfolioHighlightsROI model validated for savings and metrics by Validation Institute, a leading authority in healthcare value and economic credibilityConfirms that payors covering VIVI Cap™ can achieve meaningful cost savings and return on investmentSupports TempraMed's planned payor pilot programs aimed at confirming savings and securing reimbursement coverageEstablishes a scalable, reimbursement-driven..</description>
</item>
<item>
<title>TempraMed Closes C$2.5 Million Fully Subscribed Private Placement</title>
<link>https://6ix.com/company/tempramed-technologies-ltd/news/tempramed-closes-cdollar25-million-fully-subscribed-private-placement</link>
<guid isPermaLink="true">https://6ix.com/company/tempramed-technologies-ltd/news/tempramed-closes-cdollar25-million-fully-subscribed-private-placement</guid>
<pubDate>Mon, 12 Jan 2026 22:30:00 GMT</pubDate>
<description>Vancouver, British Columbia--(Newsfile Corp. - January 12, 2026) - TempraMed Technologies Ltd. (CSE: VIVI) (FSE: 9DY) ("TempraMed" or the "Company"), a medical-technology innovator transforming how temperature-sensitive medications are stored and managed, is pleased to announce the fully subscribed closing of its previously announced non-brokered private placement (the "Offering"), issuing 3,322,153 units (each, a "Unit") at a price of $0.76 per Unit for aggregate gross proceeds of...</description>
</item>
<item>
<title>TempraMed Receives First Commercial Order from Israel Distributor and Completes Initial Shipment Enabling Entry into National Pharmacy Network</title>
<link>https://6ix.com/company/tempramed-technologies-ltd/news/tempramed-receives-first-commercial-order-from-israel-distributor-and-completes-initial-shipment-enabling-entry-into-national-pharmacy-network</link>
<guid isPermaLink="true">https://6ix.com/company/tempramed-technologies-ltd/news/tempramed-receives-first-commercial-order-from-israel-distributor-and-completes-initial-shipment-enabling-entry-into-national-pharmacy-network</guid>
<pubDate>Tue, 06 Jan 2026 22:00:00 GMT</pubDate>
<description>Initial shipment delivered to distributor warehouse supports expansion into B2B pharmacy distribution alongside direct-to-consumer activitiesVancouver, British Columbia--(Newsfile Corp. - January 6, 2026) - TempraMed Technologies Ltd. (CSE: VIVI) (FSE: 9DY) ("TempraMed" or the "Company"), a medical-technology innovator transforming how temperature-sensitive medications are stored and managed, is pleased to announce its first commercial order in Israel and the successful delivery of an initial...</description>
</item>
<item>
<title>TempraMed Provides Positive Recap on 2025 and Strategic Outlook for 2026</title>
<link>https://6ix.com/company/tempramed-technologies-ltd/news/tempramed-provides-positive-recap-on-2025-and-strategic-outlook-for-2026</link>
<guid isPermaLink="true">https://6ix.com/company/tempramed-technologies-ltd/news/tempramed-provides-positive-recap-on-2025-and-strategic-outlook-for-2026</guid>
<pubDate>Fri, 02 Jan 2026 22:00:00 GMT</pubDate>
<description>Vancouver, British Columbia--(Newsfile Corp. - January 2, 2026) - TempraMed Technologies Ltd. (CSE: VIVI) (FSE: 9DY) ("TempraMed" or the "Company"), a medical technology innovator transforming how temperature-sensitive medications are stored and managed, is pleased to provide a positive recap on the year as well as a strategic outlook for the year ahead in 2026. As 2025 ends, the Company reflects on a transformative year marked by significant commercial progress, strategic partnerships, and...</description>
</item>
<item>
<title>TempraMed Deepens Asian Market Penetration with Expanded Distribution Partnership and Meaningful Commercial Order in South Korea</title>
<link>https://6ix.com/company/tempramed-technologies-ltd/news/tempramed-deepens-asian-market-penetration-with-expanded-distribution-partnership-and-meaningful-commercial-order-in-south-korea</link>
<guid isPermaLink="true">https://6ix.com/company/tempramed-technologies-ltd/news/tempramed-deepens-asian-market-penetration-with-expanded-distribution-partnership-and-meaningful-commercial-order-in-south-korea</guid>
<pubDate>Wed, 31 Dec 2025 22:00:00 GMT</pubDate>
<description>Expansion builds on newly granted South Korean patent, rising local demand and following the launch of digitally connected "VIVI Cap Smart" deviceVancouver, British Columbia--(Newsfile Corp. - December 31, 2025) - TempraMed Technologies Ltd. (CSE: VIVI) (FSE: 9DY) ("TempraMed" or the "Company"), a medical-technology innovator transforming how temperature-sensitive medications are stored and managed, is excited to announce today a new commercial order and an extension of its distribution...</description>
</item>
<item>
<title>TempraMed Launches New Product, VIVI Cap Smart, Expanding Its Portfolio to Include a Digital Health Offering</title>
<link>https://6ix.com/company/tempramed-technologies-ltd/news/tempramed-launches-new-product-vivi-cap-smart-expanding-its-portfolio-to-include-a-digital-health-offering</link>
<guid isPermaLink="true">https://6ix.com/company/tempramed-technologies-ltd/news/tempramed-launches-new-product-vivi-cap-smart-expanding-its-portfolio-to-include-a-digital-health-offering</guid>
<pubDate>Fri, 26 Dec 2025 22:00:00 GMT</pubDate>
<description>Integrated smart technology builds on TempraMed's proven VIVI platform, providing robust Temperature control with medication management for individuals using life-saving medicationHighlights: Expands TempraMed's product portfolio and adds a digital component to track and record medication use. First in the world platform that turns almost every insulin and GLP-1 pens to be connected and with a temperature shield. Unlocks significant pharma, healthcare provider, and real-time data opportunity...</description>
</item>
<item>
<title>TempraMed Expands U.S. Manufacturing Capacity with New Production Facility in Florida</title>
<link>https://6ix.com/company/tempramed-technologies-ltd/news/tempramed-expands-us-manufacturing-capacity-with-new-production-facility-in-florida</link>
<guid isPermaLink="true">https://6ix.com/company/tempramed-technologies-ltd/news/tempramed-expands-us-manufacturing-capacity-with-new-production-facility-in-florida</guid>
<pubDate>Wed, 17 Dec 2025 22:00:00 GMT</pubDate>
<description>New facility increases output, reduces cost of goods sold (COGS) and enhances service for B2B customers to address the forecasted increased demand for productsHighlights: Manufacturing site in Florida expands TempraMed's U.S. production footprintIncreases capacity to meet rising demand from healthcare organizations, pharmacies, payors, and device manufacturersShortens delivery timelines and improves service for customers in the United States where majority of devices have been sold to...</description>
</item>
<item>
<title>TempraMed Strengthens Global Intellectual Property Position with Grant of South Korean Patent</title>
<link>https://6ix.com/company/tempramed-technologies-ltd/news/tempramed-strengthens-global-intellectual-property-position-with-grant-of-south-korean-patent</link>
<guid isPermaLink="true">https://6ix.com/company/tempramed-technologies-ltd/news/tempramed-strengthens-global-intellectual-property-position-with-grant-of-south-korean-patent</guid>
<pubDate>Mon, 15 Dec 2025 22:00:00 GMT</pubDate>
<description>HighlightsNewly granted patent protects TempraMed's VIVI Box™ proprietary, hassle-free thermal-insulation system and smart-monitoring architectureExpands the Company's ability to adapt its core technology to a wider range of drug categories-from chronic self-injectables to complex biologicsEnhances commercialization opportunities and supports strategic engagement with leading appliance manufacturers in Asia's premium refrigeration marketVancouver, British Columbia--(Newsfile Corp. - December 15,</description>
</item>
<item>
<title>TempraMed Appoints Leading Diabetes Researcher Professor Dr. Lutz Heinemann to its Scientific Advisory Board</title>
<link>https://6ix.com/company/tempramed-technologies-ltd/news/tempramed-appoints-leading-diabetes-researcher-professor-dr-lutz-heinemann-to-its-scientific-advisory-board</link>
<guid isPermaLink="true">https://6ix.com/company/tempramed-technologies-ltd/news/tempramed-appoints-leading-diabetes-researcher-professor-dr-lutz-heinemann-to-its-scientific-advisory-board</guid>
<pubDate>Wed, 10 Dec 2025 22:00:00 GMT</pubDate>
<description>A renowned expert in insulin pharmacology, diabetes technology, and temperature-sensitive medication stability joins TempraMed to strengthen scientific leadershipVancouver, British Columbia--(Newsfile Corp. - December 10, 2025) - TempraMed Technologies Ltd. (CSE: VIVI) ("TempraMed" or the "Company"), a medical technology innovator transforming how temperature-sensitive medications are stored and managed, today announced the appointment of Professor Dr. Lutz Heinemann, one of the world's foremost</description>
</item>
<item>
<title>TempraMed Announces Strategic Agreement with Maccabi Healthcare Services, a Leading HMO with over 2.8 Million Patients</title>
<link>https://6ix.com/company/tempramed-technologies-ltd/news/tempramed-announces-strategic-agreement-with-maccabi-healthcare-services-a-leading-hmo-with-over-28-million-patients-3</link>
<guid isPermaLink="true">https://6ix.com/company/tempramed-technologies-ltd/news/tempramed-announces-strategic-agreement-with-maccabi-healthcare-services-a-leading-hmo-with-over-28-million-patients-3</guid>
<pubDate>Mon, 08 Dec 2025 22:00:00 GMT</pubDate>
<description>Vancouver, British Columbia--(Newsfile Corp. - December 8, 2025) - TempraMed Technologies Ltd. (CSE: VIVI) ("TempraMed" or the "Company"), a medical technology innovator transforming how temperature-sensitive medications are stored and managed, is pleased to announce a major commercial milestone as part of its broader global expansion strategy: its flagship products, the VIVI Cap and VIVI EPI, are now available through Maccabi Healthcare Services, Israel's second-largest health maintenance...</description>
</item>
</channel>
</rss>